Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M89,130Revenue $M25,711Net Margin (%)3.8Z-Score2.5
Enterprise Value $M93,127EPS $2.0Operating Margin %7.1F-Score4
P/E(ttm))97.8Cash Flow Per Share $0Pre-tax Margin (%)4.1Higher ROA y-yN
Price/Book4.710-y EBITDA Growth Rate %10.1Quick Ratio0.8Cash flow > EarningsY
Price/Sales3.45-y EBITDA Growth Rate %-9.5Current Ratio1.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-29.4ROA % (ttm)1.8Higher Current Ratio y-yN
Dividend Yield %4.0Insider Buy (3m)0ROE % (ttm)4.5Less Shares Outstanding y-yN
Payout Ratio %343Shares Outstanding M1,263ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with AZN

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AZNCharles Brandes 2014-09-30 Sold Out -0.35%$68.49 - $76.31
($73.2)
$ 70.57-4%Sold Out0
AZNJohn Hussman 2014-09-30 Reduce-0.29%$68.49 - $76.31
($73.2)
$ 70.57-4%Reduce -22.37%173,500
AZNGeorge Soros 2014-06-30 Buy 0.08%$62.45 - $81.09
($72.26)
$ 70.57-2%New holding, 150000 sh.150,000
AZNMario Gabelli 2014-06-30 Buy 0.02%$62.45 - $81.09
($72.26)
$ 70.57-2%New holding, 40400 sh.40,400
AZNCharles Brandes 2014-06-30 Reduce-0.78%$62.45 - $81.09
($72.26)
$ 70.57-2%Reduce -71.06%386,058
AZNJoel Greenblatt 2014-06-30 Sold Out -0.09%$62.45 - $81.09
($72.26)
$ 70.57-2%Sold Out0
AZNNWQ Managers 2014-06-30 Reduce-0.01%$62.45 - $81.09
($72.26)
$ 70.57-2%Reduce -24.55%64,475
AZNJohn Hussman 2014-03-31 Add0.96%$58.51 - $68.15
($64.29)
$ 70.5710%Add 714.29%228,000
AZNDavid Dreman 2014-03-31 Add0.14%$58.51 - $68.38
($64.41)
$ 70.5710%Add 26.61%135,439
AZNJoel Greenblatt 2014-03-31 Buy 0.09%$58.51 - $68.38
($64.41)
$ 70.5710%New holding, 95518 sh.95,518
AZNHOTCHKIS & WILEY 2014-03-31 Sold Out -0.93%$58.51 - $68.38
($64.41)
$ 70.5710%Sold Out0
AZNCharles Brandes 2014-03-31 Reduce-0.84%$58.51 - $68.15
($64.29)
$ 70.5710%Reduce -46.73%1,333,894
AZNDavid Dreman 2013-12-31 Reduce-0.34%$49.72 - $59.5
($54.28)
$ 70.5730%Reduce -40.32%106,975
AZNHOTCHKIS & WILEY 2013-12-31 Reduce-0.3%$49.72 - $59.5
($54.28)
$ 70.5730%Reduce -24.9%3,689,214
AZNJohn Hussman 2013-12-31 Reduce-0.11%$49.72 - $59.5
($54.28)
$ 70.5730%Reduce -58.82%28,000
AZNCharles Brandes 2013-09-30 Add0.12%$47.88 - $52.08
($50.24)
$ 70.5740%Add 7.92%2,381,040
AZNJohn Hussman 2013-09-30 Reduce-0.66%$47.88 - $52.08
($50.24)
$ 70.5740%Reduce -81.87%68,000
AZNHOTCHKIS & WILEY 2013-06-30 Add0.68%$47.22 - $53.01
($50.92)
$ 70.5739%Add 131.18%4,944,742
AZNJohn Hussman 2013-06-30 Reduce-1.02%$47.22 - $53.01
($50.92)
$ 70.5739%Reduce -59.76%375,000
AZNJoel Greenblatt 2013-06-30 Sold Out -0.24%$47.22 - $53.01
($50.92)
$ 70.5739%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AZN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AZN Mario Gabelli 2014-09-3041,90000.02+3.71%
AZN George Soros 2014-09-30150,0000.010.08
AZN NWQ Managers 2014-09-3064,4750.010.05
AZN David Dreman 2014-09-30117,0030.010.68-0.7%
AZN John Hussman 2014-09-30173,5000.011.1-22.37%
AZN Charles Brandes 2014-09-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


AZN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ASTRAZENECA PLC10% Owner 2014-11-12Sell2,000,000$17315.12view

Press Releases about AZN :

    Quarterly/Annual Reports about AZN:

      News about AZN:

      Articles On GuruFocus.com
      Pfizer Stocks Has A Lot Of Steam To Take The Investors Higher Jan 20 2015 
      Merck Takes A Step Forward In The World Of Medicine Jan 16 2015 
      Brandes International Equity Fund Q3 Commentary Dec 23 2014 
      Blackhill Bets Almost Half of Portfolio on Williams-Sonoma Nov 10 2014 
      A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio Nov 09 2014 
      Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
      I Believe AstraZeneca Is Fairly Valued Jul 16 2014 
      A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
      Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
      Can Pfizer Make Up Its Loss? May 09 2014 

      More From Other Websites
      BUZZ-AstraZeneca: generic Nexium arrives in US, 8 mths late Jan 27 2015
      Is a Generic Nexium Purple Pill for You? Jan 26 2015
      Teva's generic version of AstraZeneca's Nexium gets FDA approval Jan 26 2015
      FDA approves Teva's generic version of AstraZeneca's Nexium Jan 26 2015
      Duke's Rob Califf Named FDA Deputy Commissioner Jan 26 2015
      AstraZeneca's Regulatory Filing for Lesinurad Accepted - Analyst Blog Jan 26 2015
      Medivation and Astellas Report TERRAIN Data on Xtandi - Analyst Blog Jan 23 2015
      Will Pfizer (PFE) Beat Q4 Earnings Despite Generics? - Analyst Blog Jan 23 2015
      Pfizer Inc. Has AstraZeneca plc Or GlaxoSmithKline plc In Its Sights Jan 23 2015
      One dose, then surgery: A new way to test brain tumor drugs Jan 23 2015
      One dose, then surgery: A new way to test brain tumor drugs Jan 23 2015
      Leerink Raises AstraZeneca Price Target Jan 22 2015
      What distinguishes 'Box' Jan 22 2015
      BUZZ-Medivation: Cancer therapy not as safe as AstraZeneca's Jan 22 2015
      Marketing Authorisation Application for gout treatment lesinurad accepted by European Medicines... Jan 22 2015
      Astrazeneca wins European approval to market Lesinurad gout treatment Jan 22 2015
      Actavis/Gedeon Richter Present Schizophrenia Drug Data - Analyst Blog Jan 20 2015
      Why AstraZeneca plc Could Be A Major Bid Target This Year Jan 20 2015
      3 Stocks For A FTSE 100 Storm: British American Tobacco Plc, AstraZeneca plc & Reckitt Benckiser... Jan 19 2015
      Barclays Issues 3 Upgrades, 1 Downgrade On Pharma Stocks Jan 16 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK